Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) and ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.
Analyst Recommendations
This is a breakdown of recent recommendations for Capricor Therapeutics and ProQR Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Capricor Therapeutics | 1 | 6 | 4 | 0 | 2.27 |
| ProQR Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
Capricor Therapeutics currently has a consensus price target of $30.25, suggesting a potential upside of 422.90%. ProQR Therapeutics has a consensus price target of $7.60, suggesting a potential upside of 515.38%. Given ProQR Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Capricor Therapeutics.
Volatility & Risk
Capricor Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.
Insider & Institutional Ownership
21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Capricor Therapeutics and ProQR Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Capricor Therapeutics | $22.27 million | 15.10 | -$105.04 million | ($2.45) | -2.36 |
| ProQR Therapeutics | $17.99 million | 7.23 | -$47.73 million | ($0.46) | -2.68 |
ProQR Therapeutics has lower revenue, but higher earnings than Capricor Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Capricor Therapeutics and ProQR Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Capricor Therapeutics | N/A | -56.60% | -43.97% |
| ProQR Therapeutics | -223.51% | -73.83% | -35.14% |
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
